Skip to main content
SpringerLink
Log in

Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010

  • Clinical Trial Updates and Hotline Sessions
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

This article gives an overview on several novel clinical trials in the field of cardiovascular (CV) medicine which were presented during the hotline sessions and clinical trial updates at the European Society of Cardiology Congress, held in Stockholm, Sweden, from 28th August to 1st September 2010. The data have been presented by leading experts in the accordant field with relevant positions in the trials. Unpublished reports should be considered as preliminary data as the analysis may change in the final publications. The summaries presented in the manuscript were generated from the oral presentations and should provide the readers with the most comprehensive information on diagnostic and therapeutic development in CV medicine similar as previously reported Schirmer SH et al. (Clin Res Cardiol 11:691–699, 2009).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

ACS:

Acute coronary syndrome

ACT:

Activated clotting time

AF:

Atrial fibrillation

ALA:

Alpha-linolenic acid

ARB:

Angiotensin II receptor blockade

AT:

Angiotensin II

ASA:

Acetylsalicylic acid

BIMA:

Bilateral internal mammary artery

BiV:

Biventricular

BMC:

Bone marrow cell

BRMA:

Bleeding requiring medical attention

bpm:

Beats per minute

CABG:

Coronary artery bypass graft

CAD:

Coronary artery disease

CI:

Confidence interval

CV:

Cardiovascular

CVD:

Cardiovascular death

CrCl:

Creatinine clearance

CRT:

Cardiac resynchronization therapy

DES:

Drug-eluting stent

DHA:

Docosahexaenoic acids

DTI:

Direct thrombin inhibitor

DVT:

Deep vein thrombosis

EES:

Everolimus-eluting stent

HR:

Hazard ratio

i.v.:

Intravenous

EPA:

Eicosapentaenoic acid

EPO:

Erythropoetin

LVEF:

Left ventricular ejection fraction

LV:

Left ventricular

MACE:

Major adverse cardiovascular events

MI:

Myocardial infarction

mTOR:

Mammalian target of rapamycin

NSTE-ACS:

Non-ST-segment elevation acute coronary syndrome

PAR-1:

Protease activated receptor 1

PCI:

Percutaneous coronary intervention

PPS:

Postpercardiotomy syndrome

RVA:

Right ventricular apical

SIMA:

Single internal mammary artery

SES:

Sirolimus-eluting stent

SSS:

Sick sinus syndrome

TAVI:

Transcatheter aortic valve implantation

TA:

Transapical

TF:

Transfemoral

TIA:

Transient ischemic attack

TIMI:

Thrombolysis in myocardial infarction

TRAP:

Thrombin receptor activating peptide

TVR:

Target vessel revascularization

UA:

Unstable angina

UFH:

Unfractionated heparin

VKA:

Vitamin K antagonist

VTE:

Venous thromboembolism

References

  1. Schirmer SH et al (2009) Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol 98(11):691–699

    Article  CAS  PubMed  Google Scholar 

  2. Swedberg K et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885

    Article  CAS  PubMed  Google Scholar 

  3. McAlister FA et al (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150(11):784–794

    PubMed  Google Scholar 

  4. Böhm M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376(9744):886–894

    Article  PubMed  Google Scholar 

  5. Voors AA et al (2010) A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J

  6. Leonardi S et al (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 160(1):65–72

    Article  CAS  PubMed  Google Scholar 

  7. Goto S et al (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J

  8. Montalescot G et al (2006) Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 355(10):1006–1017

    Article  CAS  PubMed  Google Scholar 

  9. Schulz S et al (2010) ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J

  10. Kastrati A et al (2008) Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 359(7):688–696

    Article  CAS  PubMed  Google Scholar 

  11. Wijns W et al (2010) Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J

  12. Taggart DP et al (2010) Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART). Eur Heart J

  13. Eikelboom JW (2010) Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 159(3):348–353 e1

    Article  CAS  PubMed  Google Scholar 

  14. Ehrlich JR, Hohnloser SH, Nattel S (2006) Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27(5):512–518

    Article  CAS  PubMed  Google Scholar 

  15. Vermes E et al (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 107(23):2926–2931

    Article  PubMed  Google Scholar 

  16. Steg PG et al (2010) Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. JAMA

  17. Yu CM et al (2009) Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 361(22):2123–2134

    Article  PubMed  Google Scholar 

  18. Cleland JG et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539–1549

    Article  CAS  PubMed  Google Scholar 

  19. Maisch B et al (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25(7):587–610

    Article  PubMed  Google Scholar 

  20. Finkelstein Y et al (2002) Colchicine for the prevention of postpericardiotomy syndrome. Herz 27(8):791–794

    Article  PubMed  Google Scholar 

  21. Imazio M et al (2010) COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J [Epub ahead of print]

  22. Leontyev S et al (2009) Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. Ann Thorac Surg 87(5):1440–1445

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany

    Matthias Lenski, Felix Mahfoud, Christian Werner & Michael Böhm

  2. Abteilung für Kardiologie und Herzkreislauferkrankungen, Innere Medizin III, Eberhard Karls Universität Tübingen, Tübingen, Germany

    Axel Bauer

Authors
  1. Matthias Lenski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Felix Mahfoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Axel Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Lenski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lenski, M., Mahfoud, F., Werner, C. et al. Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010. Clin Res Cardiol 99, 679–692 (2010). https://doi.org/10.1007/s00392-010-0238-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-010-0238-3

Keywords

Search

Navigation